Transarterial Chemoembolization Combined with Apatinib for Treatment of Advanced Hepatocellular Carcinoma: Analysis of Survival and Prognostic Factors

[1] Forner A(2018)Hepatocellular carcinoma Lancet 391 1301-1314

[2] Reig M(2015)Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study Liver Int 35 2155-444

[3] Bruix J(2017)Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology Cardiovasc Intervent Radiol 37 438-1223

[4] Park JW(2017)Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy J Vasc Interv Radiol 28 1210-812

[5] Chen M(2010)Correlation of hypoxia-inducible factor 1alpha with angiogenesis in liver tumors after transcatheter arterial embolization in an animal model Cardiovasc Intervent Radiol 33 806-691

[6] Colombo M(2019)Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial J Hepatol 70 684-1210

[7] Bargellini I(2013)Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans Drug Metab Dispos 41 1195-11

[8] Florio F(2019)Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging Exp Mol Med 51 1-4583

[9] Golfieri R(2018)Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma Cancer Med 7 4570-327

[10] Gaba RC(2019)The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study Cancer Biol Ther 20 321-438

[1] Forner A(2018)Hepatocellular carcinoma Lancet 391 1301-1314

[2] Reig M(2015)Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study Liver Int 35 2155-444

[3] Bruix J(2017)Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology Cardiovasc Intervent Radiol 37 438-1223

[4] Park JW(2017)Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy J Vasc Interv Radiol 28 1210-812

[5] Chen M(2010)Correlation of hypoxia-inducible factor 1alpha with angiogenesis in liver tumors after transcatheter arterial embolization in an animal model Cardiovasc Intervent Radiol 33 806-691

[6] Colombo M(2019)Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial J Hepatol 70 684-1210

[7] Bargellini I(2013)Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans Drug Metab Dispos 41 1195-11

[8] Florio F(2019)Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging Exp Mol Med 51 1-4583

[9] Golfieri R(2018)Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma Cancer Med 7 4570-327

[10] Gaba RC(2019)The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study Cancer Biol Ther 20 321-438